Biogen, Eisai's Alzheimer's Drug Deemed Too Costly for UK National Health Service
Biogen, Eisai's Alzheimer's Drug Deemed Too Costly for UK National Health Service
渤健公司和Eisai的阿爾茨海默病藥物被認爲對英國國家醫療保健系統而言過於昂貴
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊